文献速递淋巴瘤

皮下莫妥珠单抗联合维泊妥珠单抗对比利妥昔单抗联合维泊妥珠单抗治疗复发/难治性大B细胞淋巴瘤的随机II期研究

A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B-Cell Lymphoma.
PubMed 文献 · Am J Hematol · 2026-06-12

该随机II期研究纳入80例复发/难治性大B细胞淋巴瘤患者,比较皮下莫妥珠单抗联合维泊妥珠单抗(Mosun-Pola)与利妥昔单抗联合维泊妥珠单抗(R-Pola)的疗效。主要终点最佳客观缓解率在Mosun-Pola组为77.5%,R-Pola组为50.0%;完全缓解率分别为55.0%和35.0%。中位无进展生存期分别为25.4个月和6.4个月(HR 0.47),固定疗程Mosun-Pola在所有疗效终点上均优于R-Pola。

要点

  • Mosun-Pola组最佳ORR为77.5%,显著高于R-Pola组的50.0%。
  • Mosun-Pola组中位PFS为25.4个月,R-Pola组为6.4个月(HR 0.47)。
  • Mosun-Pola组细胞因子释放综合征发生率为12.5%,均为1/2级。

核心结论

  • 固定疗程皮下Mosun-Pola在复发/难治性大B细胞淋巴瘤中所有疗效终点均优于R-Pola。

研究设计与样本

  • 随机II期研究,纳入80例复发/难治性大B细胞淋巴瘤患者,随机分配至Mosun-Pola组(n=40)或R-Pola组(n=40)。
  • Mosun-Pola组接受皮下莫妥珠单抗(第1周期阶梯剂量5/45/45 mg,后45 mg)联合维泊妥珠单抗(1.8 mg/kg IV);R-Pola组接受利妥昔单抗(375 mg/m2 IV)联合维泊妥珠单抗。

主要发现

  • 最佳客观缓解率:Mosun-Pola组77.5%(95%CI 61.6-89.2),R-Pola组50.0%(95%CI 33.8-66.2)。
  • 完全缓解率:Mosun-Pola组55.0%(95%CI 38.5-70.7),R-Pola组35.0%(95%CI 20.6-51.7)。
  • 中位无进展生存期:Mosun-Pola组25.4个月,R-Pola组6.4个月(HR 0.47)。
  • 中位总生存期:Mosun-Pola组未达到,R-Pola组25.5个月(HR 0.78)。
  • 细胞因子释放综合征发生率:Mosun-Pola组12.5%,均为1/2级。

临床怎么用

  • 对于复发/难治性大B细胞淋巴瘤,固定疗程皮下Mosun-Pola可能提供优于R-Pola的缓解和生存获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mosunetuzumab plus polatuzumab vedotin has shown promising activity versus rituximab plus polatuzumab vedotin (R-Pola) in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL; NCT03671018). We present results from the Phase II randomized cohort, evaluating subcutaneous mosunetuzumab plus polatuzumab vedotin (Mosun-Pola), with > 2 years of follow-up. Patients with R/R LBCL and ≥ 1 prior line of therapy were randomized to receive Mosun-Pola or R-Pola. Mosunetuzumab was administered subcutaneously with Cycle (C) 1 step-up dosing (5/45/45 mg) then 45 mg on C2 Day (D) 1-C8D1 (21-day cycles). Polatuzumab vedotin (1.8 mg/kg) was given intravenously (IV) on D1 of C1-6. Rituximab IV (375 mg/m2) was given on D1 of C1-8. Primary endpoint was best objective response rate (ORR). As of November 15, 2024, 80 patients had been enrolled (Mosun-Pola, n = 40; R-Pola, n = 40). Best ORR was 77.5% (95% confidence interval [CI] 61.6-89.2) for Mosun-Pola and 50.0% (95% CI: 33.8-66.2) for R-Pola; complete response (CR) rates were 55.0% (95% CI: 38.5-70.7) and 35.0% (95% CI: 20.6-51.7), respectively. Median progression-free survival was 25.4 months for Mosun-Pola and 6.4 months for R-Pola (hazard ratio [HR] 0.47); median overall survival was not reached and 25.5 months (HR: 0.78), respectively. Cytokine release syndrome occurred in 12.5% of Mosun-Pola-treated patients (all Grade 1/2). Fixed-duration Mosun-Pola demonstrated benefit across all efficacy endpoints compared with R-Pola in patients with R/R LBCL. These findings are consistent with the observed benefit of Mosun-Pola for patients with R/R LBCL in the global Phase III SUNMO study (NCT05171647). Trial Registration: Clinicaltrials.gov number: NCT03671018.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Chavez JC, Bastos-Oreiro M, Diefenbach C, et al. A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B-Cell Lymphoma. Am J Hematol. 2026. PMID: 42283231. doi:10.1002/ajh.70403

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。